(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
7 Well known Vacation spots In The US - 2Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene
- 3Cruising Solo All over the Planet: An Excursion of Self-Disclosure
- 4Mom finds out she has cancer after noticing something was off while breastfeeding
- 5Which Breakfast Enraptures Your Taste Buds? Vote
- The 15 Most Motivating TED Discusses All Time
- The Best Cell phone Brands for Tech Lovers
- Sa'ar warns German delegation: 'A Palestinian state would be a Hamas terror state'
- A Couple of Modest Guitars for 2024
- Study shows no clear link between low-fat dairy and dementia risk
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- Heart disease risk greater for women with a common condition they may not be aware they have
- Israeli president concerned over proposed renaming of park
- Experience Is standing by: History's Most noteworthy Travelers
